A single-center review of pre-exposure prophylaxis with tixagevimab-cilgavimab in solid organ transplant recipients.
Faiza MoradoRoland DavoudiPnada Kawewat-HoNeha NandaRachel CartusSuhail A ShaikhPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2023)
Our study results, which included months when BA.5 was in increased circulation, suggest no significant difference in COVID-19 infection with or without use of tix-cil PrEP in our solid organ transplant groups. As the COVID-19 pandemic continues to evolve, clinical utility of tix-cil should be evaluated against new, emerging strains.